S&P Futures
3,835.50 +1.50 (+0.04%) Dow Futures
30,920.00 -16.00 (-0.05%) Nasdaq Futures
11,823.50 +15.00 (+0.13%) Russell 2000 Futures
1,739.80 -1.90 (-0.11%) Crude Oil
100.06 +0.56 (+0.56%) Gold
1,767.00 +3.10 (+0.18%)
Alpine Immune Sciences, Inc. (ALPN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 8.61 |
| Open | 8.45 |
| Bid | 6.00 x 800 |
| Ask | 10.13 x 800 |
| Day's Range | 8.45 - 9.00 |
| 52 Week Range | 6.00 - 14.40 |
| Volume | |
| Avg. Volume | 112,554 |
| Market Cap | 272.653M |
| Beta (5Y Monthly) | 1.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.75 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ALPN
Related Research
- Alpine Immune Sciences, Inc.Daily – Vickers Top Buyers & Sellers for 02/17/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat5 months agoArgus Research
- Zacks
Revolution Medicines, Inc. (RVMD) Surges 5.6%: Is This an Indication of Further Gains?
Revolution Medicines, Inc. (RVMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Simply Wall St.
Great news for Alpine Immune Sciences, Inc. (NASDAQ:ALPN): Insiders acquired stock in large numbers last year
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
- Business Wire
Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer
SEATTLE, June 07, 2022--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the appointment of industry veteran Andrew S. Sandler, M.D., as its Chief Medical Officer. Dr. Sandler joins Alpine from Kiadis Pharma, a Sanofi Company, where he was Chief Medical Officer. Dr. Sandler’s anticipated start date is August 17, 2022.
